Our experienced team and knowledgeable external consultants, bring extensive product development and regulatory expertise to the execution of our clinical development plan, and the navigation of manufacturing, quality and regulatory hurdles. Our research team and advisors include scientists who:
- have been involved in discovering genes associated with Alzheimer’s disease;
- have conducted trials that brought to FDA approval drugs like Aricept and Namenda for Alzheimer’s disease; and
- are expert on amyloid-beta plaque formation
We have filed or licensed numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates. Our intellectual property, including our patents, includes the use of ALZT-OP1a for treatment of Alzheimer’s disease, use of ALZT-OP1a and ALZT-OP1b as a combination therapy for the treatment of Alzheimer’s disease, use of the ALZT-OP platform for treating neurodegeneration associated with amyloidal plaques, improving brain uptake of drugs (including the ALZT-OP platform), improving the quality of life of Alzheimer’s disease sufferers, inhibiting plaque formation with several drug structures, dosing subjects with specific formulations, increasing deep lung penetration of dry powder such as ALZT-OP1a and the design and use of a new single dose disposable inhaler.
We have obtained a worldwide exclusive license to patents and patent applications from the Massachusetts General Hospital. These assets cover our lead technologies and include additional indications that are outside the field of neurology, such as drug delivery with an inhaler or the use of specific targeting and brain penetration enhancement molecules.